MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease

Journal of Hepatology

Volumn 64, Issue 3, 2016, Pages 682-690

  Petta, Salvatore ^a   Valenti, Luca ^b   Marra, Fabio ^c   Grimaudo, Stefania ^a   Tripodo, Claudio ^a   Bugianesi, Elisabetta ^d   Cammà, Calogero ^a   Cappon, Andrea ^c   Di Marco, Vito ^a   Di Maira, Giovanni ^c   Dongiovanni, Paola ^b   Rametta, Raffaela ^b   Gulino, Alessandro ^a   Mozzi, Enrico ^b   Orlando, Emanuele ^a   Maggioni, Marco ^b   Pipitone, Rosaria Maria ^a   Fargion, Silvia ^b   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Fibrosis; MERTK; NASH

Indexed keywords

PROCOLLAGEN; MERTK PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MIGRATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FIBROGENESIS; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALY; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MERTK GENE; MIDDLE AGED; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STELLATE CELL; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; GENETICS; LIVER CIRRHOSIS;

ADULT; ANIMALS; CELLS, CULTURED; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MICE, INBRED BALB C; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, MESSENGER;

EID: 84958880042     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.10.016     Document Type: Article

References (35)

1. S. Petta, C. Muratore, and A. Craxì Non-alcoholic fatty liver disease pathogenesis: the present and the future Dig Liver Dis 41 2009 615 625
2. G. Marchesini, E. Bugianesi, G. Forlani, and et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome Hepatology 37 2003 917 923
3. G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study Hepatology 42 2005 44 52
4. S. Petta, and A. Craxì Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association Curr Pharm Des 16 2010 741 752
5. G. Targher, F. Marra, and G. Marchesini Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51 2008 1947 1953
6. S. Petta, C. Tripodo, S. Grimaudo, and et al. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis Dig Liver Dis 2011 [Epub ahead of print] PubMed PMID: 21324757
7. D. van der Poorten, K.L. Milner, J. Hui, and et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease Hepatology 48 2008 449 457
8. E. Bugianesi, G. Marchesini, E. Gentilcore, and et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis Hepatology 44 2006 1648 1655
9. C.K. Argo, P.G. Northup, A.M. Al-Osaimi, and et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis J Hepatol 51 2009 371 379
10. P. Dongiovanni, Q.M. Anstee, and L. Valenti Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment Curr Pharm Des 19 2013 5219 5238
11. L. Valenti, A. Al-Serri, A.K. Daly, E. Galmozzi, R. Rametta, and et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease Hepatology 51 2010 1209 1217
12. P. Dongiovanni, S. Petta, C. Maglio, A.L. Fracanzani, R. Pipitone, E. Mozzi, and et al. TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease Hepatology 2014 10.1002/hep.27490
13. Y.L. Liu, H.L. Reeves, A.D. Burt, D. Tiniakos, S. McPherson, J.B. Leathart, and et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease Nat Commun 5 2014 4309
14. E. Patin, Z. Kutalik, J. Guergnon, S. Bibert, B. Nalpas, E. Jouanguy, and et al. Swiss Hepatitis C Cohort Study Group; International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection Gastroenterology 143 2012 1244 1252
15. R.M. Linger, A.K. Keating, H.S. Earp, and D.K. Graham TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer Adv Cancer Res 100 2008 35 83
16. G. Zizzo, B.A. Hilliard, M. Monestier, and P.L. Cohen Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction J Immunol 189 2012 3508 3520
17. S. De Minicis, E. Seki, H. Uchinami, J. Kluwe, Y. Zhang, D.A. Brenner, and et al. Gene expression profiles during hepatic stellate cell activation in culture and in vivo Gastroenterology 132 2007 1937 1946
18. G. Zizzo, and P.L. Cohen The PPAR-γ antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-γ in human macrophage polarization J Inflamm (Lond) 12 2015 36
19. A. Fourcot, D. Couchie, M.N. Chobert, E.S. Zafrani, P. Mavier, Y. Laperche, and et al. Gas6 deficiency prevents liver inflammation, steatohepatitis, and fibrosis in mice Am J Physiol Gastrointest Liver Physiol 300 2011 G1043 G1053
20. L. Valenti, R. Rametta, M. Ruscica, P. Dongiovanni, L. Steffani, B.M. Motta, and et al. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls BMC Gastroenterol 12 2012 111
21. American Diabetes Association Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: Clinical Practice Recommendations Committee Report Diabetes Care 2000 2000 S4 S19
22. D.R. Matthews, J.P. Hosker, A.S. Rudenski, and et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
23. G. Colloredo, M. Guido, A. Sonzogni, and G. Leandro Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease J Hepatol 39 2003 239 244
24. D.E. Kleiner, E.M. Brunt, M. Van Natta, and et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 411 2005 313 321
25. A. Provenzano, S. Milani, F. Vizzutti, W. Delogu, N. Navari, E. Novo, and et al. N-3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis Liver Int 34 2014 918 930
26. R. Bruno, S. Galastri, P. Sacchi, S. Cima, A. Caligiuri, R. DeFranco, and et al. Gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis Gut 59 2010 513 520
27. G. Di Maira, F. Brustolon, J. Bertacchini, K. Tosoni, S. Marmiroli, L.A. Pinna, and et al. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level Oncogene 18 2007 6915 6926
28. E. Rovida, N. Navari, A. Caligiuri, P. Dello Sbarba, and F. Marra ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells J Hepatol 48 2008 107 115
29. SAS Technical Report, SAS/STAT software: changes and enhancement, Release 6.07 1992 SAS Institute, Inc. Cary, NC
30. R. Rametta, E. Mozzi, P. Dongiovanni, B.M. Motta, M. Milano, G. Roviaro, and et al. Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects Int J Obes (Lond) 37 2013 986 992
31. S. Christoph, D. Deryckere, J. Schlegel, J.K. Frazer, L.A. Batchelor, A.Y. Trakhimets, and et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo Mol Cancer Ther 12 2013 2367 2377
32. S. Rüeger, P.Y. Bochud, J.F. Dufour, B. Müllhaupt, D. Semela, M.H. Heim, and et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C Gut 2014 10.1136/gutjnl-2014-306997 pii: gutjnl-2014-306997
33. F. Marra, M.C. Arrighi, M. Fazi, A. Caligiuri, M. Pinzani, R.G. Romanelli, and et al. Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat Hepatology 30 1999 951 958
34. F. Lafdil, M.N. Chobert, D. Couchie, A. Brouillet, E.S. Zafrani, P. Mavier, and et al. Induction of Gas6 protein in CCl4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells Hepatology 44 2006 228 239
35. D. Huang, and I. Ovcharenko Identifying causal regulatory SNPs in ChIP-seq enhancers Nucleic Acids Res 43 2015 225 236